Plandai Biotechnology, Inc. Expands Global Distribution Of Phytofare™ Extracts With Agreement For European Markets

SEATTLE, May 2, 2013 /PRNewswire/ -- Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced an agreement under which Willows Ingredients, Ltd. of Ireland  will distribute Plandai's Phytofare™ extracts into European markets.

Targeted industries included in the agreement are the medical, nutraceutical and animal sectors.  Willows Ingredients will have exclusive rights sell and market Phytofare™ to its existing customer base as well as to new customers it adds during the term of the agreement.

Willows Ingredients (www.willowsingredients.ie) is an Irish based, family-owned distributor of raw materials for food, healthcare, sports and animal nutrition industries.  The company primarily represents, on an exclusive agreement basis, manufacturers of raw materials used in products for the above markets.  Willows works closely with its customers and suppliers on a partnership basis and offers a high level of client service coupled with fast, accurate and reliable responses to both clients and suppliers.

"We continue to focus on securing agreements with highly reputable distributors that have developed extensive clients bases in targeted markets around the world," said Callum Baylis-Duffield, Vice-President and Global Director, Marketing Sales for Plandai Biotechnology.  "Agreements like the one with Willows Ingredients will ensure that as we expand production of our Phytofare™ extracts, we will have robust distribution channels already in place in order to achieve corresponding sales growth."

David Scrivens, Managing Director of Willows Ingredients, stated: "We are very excited to have entered into partnership with Phyto Nutricare to market and sell the Phytofare™ range of products in Europe. We feel the Phytofare™ range will be excellent products both for our existing customers and potential new customers and fit perfectly as part of our continued expansion across the European Health & Supplement areas."

In published USDA studies, Plandai's proprietary plant extracts, including Phytofare™ Catechin, Bioflavonoid and Limonoid Glucoside Complex, and Carotenoid botanical extracts, have shown to have improved bioavailability – the degree to which a substance becomes available to the target tissue after administration – of between 60-80%, far exceeding anything available today.  Superior levels of bioavailability simply mean that the body can actually receive the benefits promised on the product label.

The Company believes that its technology is the foundation for creating an entirely new family of drugs that can treat a multitude of diseases and conditions safely and affordably using naturally-derived extracts. 

About Plandai Biotechnology, Inc.

Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.  Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing Phytofare™ botanical extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process.  Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical.  For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement

The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandai's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandai is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.

Contact: 
Andrew Beyer
Phone: 619-202-7456
Email:  investor@Plandaíbiotech.com

SOURCE Plandai Biotechnology, Inc.